Products
Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-864
Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inbakicept is a human IL-15 superagonist with immunostimulatory properties with promising anti-cancer treatment and it is also being investigated as an HIV treatment. Inbakicept is a soluble complex consisting of two protein subunits of a human interleukin (IL)-15 variant (nogapendekin alfa) bound with high affinity to a dimeric human IL-15 receptor α (IL-15 Rα) sushi domain/human IgG1 Fc fusion protein. This fusion protein has been designed to simulate the normal mechanism of action of IL-15 where IL-15 and IL-15 Rα are coordinately expressed by antigen-presenting cells (monocytes and dendritic cells) and presented in trans to neighboring NK cells or CD8 + T cells expressing the CD122/CD132 receptor complex.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-864-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-864-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-864-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-864-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) |
| INN Name | Inbakicept |
| Target | IL15 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Altor BioScience (FL USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
